Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14992607 | 0.85 | THRB (0.38) | THRBKMT2ACYP3A4MEN1HPGD | |
| SCHEMBL2381870 | 0.85 | CYP3A4 (0.42) | THRBKMT2ACYP3A4MEN1HPGD | |
| SCHEMBL17059410 | 0.83 | THRB (0.37) | THRBKMT2ACYP3A4MEN1HPGD | |
| SCHEMBL598166 | 0.80 | CYP3A4 (0.50) | KMT2ACYP3A4MEN1HPGDPDE10A | |
| SCHEMBL698413 | 0.79 | KDM4E (0.46) | KMT2ACYP3A4MEN1HPGDALDH1A1 | |
| SCHEMBL20670043 | 0.78 | POLB (0.39) | THRBKMT2ACYP3A4MEN1PDE10A | |
| SCHEMBL26418160 | 0.78 | SLC6A2 (0.34) | THRBKMT2AMEN1TSHRKDM4E | |
| SCHEMBL30046662 | 0.77 | KMT2A (0.45) | THRBKMT2ACYP3A4MEN1HPGD | |
| SCHEMBL2380154 | 0.77 | CYP3A4 (0.61) | THRBKMT2ACYP3A4MEN1HPGD | |
| Oxalic Acid SCHEMBL2892582 | 0.76 | CYP3A4 (0.47) | KMT2ACYP3A4MEN1HPGDPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION | 2021-07-27 | — | — | US | disclosed |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2020-03-17 | — | — | US | disclosed |
| EP-2785714-B1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2018-11-21 | — | — | EP | disclosed |
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | DEVELOPMENT CENTER OF BIOTECHNOLOGY (TW) | 2018-11-08 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-9409902-B2 | Modulators of HEC1 activity and methods therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2016-08-09 | — | — | US | disclosed |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORP (TW) | 2015-09-10 | — | — | US | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| EP-2547676-B1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC (TW) | 2015-07-29 | — | — | EP | disclosed |
| WO-2013082324-A1 | IMPROVED MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS CORPORATION (TW) | 2013-06-06 | — | — | WO | disclosed |
| EP-2547676-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | Taivex Therapeutics Inc. (TW) | 2013-01-23 | — | — | EP | disclosed |
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | ALNYLAM PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | TAIVEX THERAPEUTICS CORPORATION (TW) | 2011-09-22 | — | — | US | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011115998-A2 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | TAIVEX THERAPEUTICS INC. (CN) | 2011-09-22 | — | — | WO | disclosed |
| WO-2010001220-A1 | NEW 1,2,4-TRIAZINE DERIVATIVES AND BIOLOGICAL APPLICATIONS THEREOF | MUTABILIS SA (FR) | 2010-01-07 | — | — | WO | disclosed |
| EP-2141164-A1 | New 1,2,4-triazine derivatives and biological applications thereof | Mutabilis (FR) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180318310-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | THRB 3798/4885KMT2A 1862/4885CYP3A4 3983/4885 |
| US-20110313144-A1 | iRNA Agents Targeting CCR5 Expressing Cells And Uses Thereof | CCR5, CXCR3, CCR2 | THRB 1513/4885KMT2A 3682/4885CYP3A4 4874/4885 |
| US-20150250794-A1 | MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | WEE1, WEE2, NEK11 | THRB 3798/4885KMT2A 1862/4885CYP3A4 3983/4885 |
| US-10588909-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | THRB 3798/4885KMT2A 1862/4885CYP3A4 3983/4885 |
| US-11071736-B2 | Modulators of HEC1 activity and methods therefor | WEE1, WEE2, NEK11 | THRB 3798/4885KMT2A 1862/4885CYP3A4 3983/4885 |
| US-20110230486-A1 | Modulators Of HEC1 Activity And Methods Therefor | WEE1, WEE2, NEK11 | THRB 3699/4885KMT2A 1659/4885CYP3A4 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.